Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dextrothyroxine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB known ✓ | P10828 | 11/20 | 0.74 |
| ▸ | THRA known ✓ | P10827 | 7/20 | 0.74 |
| ▸ | USP2 | O75604 | 4/20 | 0.76 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.76 |
| ▸ | MEN1 | O00255 | 7/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.74 |
| ▸ | LMNA | P02545 | 5/20 | 0.74 |
| ▸ | PPARG | P37231 | 5/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.74 |
| ▸ | TTR | P02766 | 2/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.74 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.74 |
| ▸ | MAPT | P10636 | 2/20 | 0.74 |
| ▸ | RXRA | P19793 | 2/20 | 0.74 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.74 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.74 |
| ▸ | HTR1A | P08908 | 1/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dextrothyroxine SCHEMBL838270 | 1.00 | USP2 (0.76) | USP2L3MBTL1THRBMEN1KMT2A | |
| Dextrothyroxine SCHEMBL2327406 | 1.00 | USP2 (0.76) | USP2L3MBTL1THRBMEN1KMT2A | |
| Dextrothyroxine SCHEMBL5498887 | 0.99 | THRB (0.76) | USP2L3MBTL1THRBMEN1KMT2A | |
| Dextrothyroxine SCHEMBL34102 | 0.99 | THRB (0.76) | USP2L3MBTL1THRBMEN1KMT2A | |
| Dextrothyroxine SCHEMBL582058 | 0.99 | THRB (0.76) | USP2L3MBTL1THRBMEN1KMT2A | |
| Dextrothyroxine SCHEMBL1995243 | 0.99 | THRB (0.76) | USP2L3MBTL1THRBMEN1KMT2A | |
| Levothyroxine SCHEMBL1560691 | 0.94 | THRB (0.86) | USP2L3MBTL1THRBMEN1KMT2A | |
| Levothyroxine SCHEMBL4965467 | 0.94 | THRB (0.86) | USP2L3MBTL1THRBMEN1KMT2A | |
| Dextrothyroxine SCHEMBL15569465 | 0.91 | THRB (0.91) | USP2L3MBTL1THRBMEN1KMT2A | |
| Dextrothyroxine SCHEMBL4437395 | 0.87 | THRB (0.61) | USP2L3MBTL1THRBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119233828-A | Nano encapsulated pharmaceutical composition and use thereof | 福君基因公司 | 2024-12-31 | — | — | CN | disclosed |
| CN-119212725-A | Polymer nano aggregate pharmaceutical composition and application thereof | ANP科技公司 | 2024-12-27 | — | — | CN | disclosed |
| CN-112004520-B | Modified release pharmaceutical powder compositions comprising a gastric raft formation system with triggered pulsatile drug release | 特瑞斯制药公司 | 2024-08-23 | — | — | CN | disclosed |
| CN-116940351-A | Prodrug compositions and methods of treatment | 阿奎斯蒂弗医疗股份有限公司 | 2023-10-24 | — | — | CN | disclosed |
| CN-109789216-B | Topical skin treatment formulations based on ionic species | 加利福尼亚大学董事会 | 2023-05-23 | — | — | CN | disclosed |
| CN-116157129-A | Pharmaceutical combinations and their use in cancer treatment | 因代雷斯有限公司 | 2023-05-23 | — | — | CN | disclosed |
| US-20030032578-A1 | Antifungal and antiparasitic compounds | UNITED STATES GOVERNMENT | 2003-02-13 | — | — | US | disclosed |
| US-6403576-B1 | CHOLESTEROL SYNTHESIS INHIBITOR | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY | 2002-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032578-A1 | Antifungal and antiparasitic compounds | PIGO, CAT, ERG28 | THRB 3884/4885THRA 4025/4885USP2 3649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.